Vial Doses First Patient with Asthma in Phase 1b Study of Vial's IL-13 x TSLP, a Bispecific Antibody Designed for Twice-Yearly Dosing
Vial's IL-13 x TSLP is designed to deliver breadth, depth, and durability of Type 2 disease control in a single half-life-extended antibody Phase 1a data in healthy volunteers (15–800 mg IV) support progression into patients, with pharmacokinetics that could support twice-yearly (Q6M)...